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Human DC-SIGN and CD23 do not 
interact with human IgG
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Arthur E. H. Bentlage1, Zoltán Szittner1, Ninotska I. L. Derksen2, Manfred Wuhrer  3, 
Theo Rispens2 & Gestur Vidarsson  1
The precise mechanisms underlying anti-inflammatory effects of intravenous immunoglobulin (IVIg) 
therapies remain elusive. The sialylated IgG fraction within IVIg has been shown to be therapeutically 
more active in mouse models. Functionally, it has been suggested that IgG undergoes conformational 
changes upon Fc-sialylation which sterically impede binding to conventional FcγRs, but simultaneously 
allow binding to human DC-SIGN (SIGN-R1 in mice) and also CD23. These latter C-type lectins have been 
proposed responsible for the immunomodulatory effects in mouse models. However, there is conflicting 
evidence supporting direct interactions between sialylated human IgG and CD23/DC-SIGN. While cells 
expressing human CD23 and DC-SIGN in their native configuration bound their natural ligands IgE and 
ICAM-3, respectively, no IgG binding was observed, regardless of Fc-glycan sialylation in any context 
(with or without bisection and/or fucosylation) or presence of sialylated Fab-glycans. This was tested by 
both by FACS and a novel cellular Surface Plasmon Resonance imaging (cSPRi) approach allowing for 
monitoring low-affinity but high-avidity interactions. In summary, we find no evidence for human CD23 
or DC-SIGN being bona fide receptors to human IgG, regardless of IgG Fc- or Fab-glycosylation status. 
However, these results do not exclude the possibility that either IgG glycosylation or C-type lectins 
affect IVIg therapies.
Human immunoglobulin G (IgG) molecules contain a conserved N-linked glycan in their crystallizable fragment 
(Fc) at the asparagine residue at position 297 (N297). In addition, approximately 15% of total IgGs have N-glycans 
in the antigen binding fragment (Fab) in the antigen binding part (VH and VL domains)1,2. These glycans have 
a biantennary core structure compose d of mannose and N-acetylglucosamine (GlcNAc) residues which can be 
extended with other sugar moieties such as fucose, galactose and sialic acid. Fc-glycans are required for the open 
conformation of the CH2 region of the IgG Fc domain to facilitate binding of Fc gamma receptors (FcγRs)3. 
Subtle changes in Fc-glycan composition influence the affinity of IgG for FcγRs and effector functions4. For exam-
ple, it is well established that afucosylated IgG has an enhanced binding affinity to FcγRIIIa and FcγRIIIb4–8. 
Recently, it has become apparent that galactosylation, which has less effect on binding affinity of fucosylated IgG 
to FcγR, further enhances binding affinity of afucosylated IgG to FcγRIIIa/b7,9. Notably, the elevated binding of 
these IgG glycoforms to members of the FcγRIII family (FcγRIV in mice) seems to be related to the fact that only 
these receptors have an N-linked glycan at position 162 that also directly interacts with the IgG Fc-glycan, caus-
ing favorable binding to afucosylated IgG10–12. Irrespective of the fucosylation status, IgG Fc-galactosylation and 
-sialylation, increases the binding of IgG to C1q and thereby affects classical complement activation7,13. Therefore, 
IgG glycosylation encodes for an important immunomodulatory ability.
Because of its anti-inflammatory effect, intravenous immunoglobulin (IVIg) therapy is used to treat a wide 
range of patients with autoimmune diseases and other inflammatory conditions. The precise mechanisms 
underlying this treatment still remain to be elucidated. The current ideas are that several mutually nonexclusive 
mechanisms exist, IgG Fab- and/or Fc-mediated, that are responsible for its clinical actions14. Because of the 
immunomodulatory potential, IgG glycosylation has been suggested to be an additional factor responsible for the 
effectiveness of IVIg treatment15–20. During the last decade, a considerable amount of prominent work has been 
put forward hinting at an alternative mechanism17,18,21–23. One suggested mechanism is that the IVIg fraction with 
sialylated Fc (approximately 16% of total IVIg24) is responsible for the anti-inflammatory effect via the C-type 
1Department experimental immunohematology, Sanquin Research and Landsteiner Laboratory, Academic 
Medical centre, University of Amsterdam, Amsterdam, the netherlands. 2Department immunopathology, Sanquin 
Research and Landsteiner Laboratory, Academic Medical centre, University of Amsterdam, Amsterdam, the 
netherlands. 3center for Proteomics and Metabolomics, Leiden University Medical center, Leiden, the netherlands. 
correspondence and requests for materials should be addressed to G.V. (email: G.Vidarsson@sanquin.nl)
Received: 18 December 2018
Accepted: 20 June 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:9995  | https://doi.org/10.1038/s41598-019-46484-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
lectin DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-integrin), which has been designated by some as a 
type II FcR25. Another member of this Type II FcR family is the C-type lectin CD23 (low affinity receptor for IgE 
Fc). In the proposed mechanism, these homologous receptors (both located on chromosome 1926) can both bind 
the IgG CH2-CH3 interphase, in a similar fashion as CD23 binds to IgE23. IgG binding to DC-SIGN, found on 
regulatory macrophages and dendritic cells, has been reported to result in the release of regulatory cytokines and 
subsequently upregulation of the inhibitory FcγRIIb on effector macrophages, causing an increased threshold for 
inflammation17,19,25. IgG binding to CD23, found on mature B-cells, has also been reported to cause upregulation 
of FcγRIIb, which increases the threshold for B-cell receptor signaling and affects Ig-affinity maturation27,28.
According to this model, CD23 and DC-SIGN only bind to IgG, in a calcium-dependent manner, when the 
IgG Fc-glycan is α2,6-sialylated. Upon sialylation, the Fc domain was hypothesized to undergo a conforma-
tional change from an “open” to a “closed” state23. However, follow-up work has suggested that these structural 
changes are minimal and confined to the CE loop in the upper CH2 region29,30. In addition, direct evidence for 
the interaction between IgG and CD23/DC-SIGN consists of two cell-based ELISA assays demonstrating that 
CD23/DC-SIGN-expressing Chinese hamster ovary (CHO) cells preferentially bind to sialylated human IgG Fc 
derived from IVIg or recombinant human IgG118,23. Predicted interactions between crystal structures and the 
effects that can be observed in in vitro and in vivo tests provide further indirect evidence18,21,25,27,28,31,32. One of 
these in vivo studies used a transgenic mouse model in which a SIGN-R1 (specific ICAM-grabbing non-integrin 
R1) knock-out resulted in an abolishment of the anti-inflammatory response after administration of sialylated 
IgG21. Transgenic expression of human DC-SIGN in these SIGN-R1-deficient mice resulted in restoration of this 
immunomodulatory response27,28.
However, a considerable amount of contradictive studies emerged, mostly showing that DC-SIGN is not 
involved and/or sialylated IgG is not a stronger anti-inflammatory substance in several in vitro functional 
assays15,20,33,34 and/or in mouse models35–37. Some studies have suggested that it is not sialylation in the Fc but 
rather sialylation in the Fab domain that may exert certain anti-inflammatory effects20, while others found no 
additional effect of Fab-sialylated IVIg36. One group demonstrated that binding of recombinant DC-SIGN tetram-
ers to hexameric IgG Fc-based scaffolds does not depend on sialylation, but rather on high-mannose levels on 
the N-linked glycan38, which was also found in the glycan binding assays performed by Guo et al.39. Interestingly, 
Yu et al. demonstrated in an ELISA-based study that well-characterized sialylated IgG Fc fragments do not bind 
directly to human DC-SIGN40.
For most of these binding studies, either a well-defined set of glyco-engineered IgG was lacking18,23, or the 
human CD23-IgG interaction was not studied40. The aforementioned controversies, extensively reviewed else-
where41,42, need to be settled.
To study this in more detail, we extensively investigated the direct binding between native human CD23/
DC-SIGN and a well-characterized set of human IgG glycoforms. In addition to flow cytometry analysis, we also 
used a biosensor platform allowing us to study low affinity and avidity interactions for both receptors CD23 and 
DC-SIGN expressed in its native configuration on cells. Furthermore, the context of the IgG α2,6-sialylation was 
studied, by including both Fab-sialylated IgG and altering the naturally-occurring variable glycan adducts in the 
sialylated Fc-glycan, in any possible combination.
Results
Generation of human IgG1 glycoforms. In order to test whether IgG glycosylation determines the bind-
ing capacity to the proposed IgG Fc receptors DC-SIGN and CD23, we first generated a defined set of glyco-engi-
neered recombinant human IgG1 variants (Fig. 1)7,43. Our choice for IgG1 was based on the fact that it comprises 
the largest fraction in IVIg (approximately 60%)44 and because studies demonstrating direct binding of sialylated 
IgG to CD23/DC-SIGN all used Fc fragments which originated either from IVIg or recombinant human IgG118,23. 
Also the immunomodulatory effects in mouse models that have been shown for sialylated IgG from IVIg18,22,45 
could be fully recapitulated by sialylated recombinant human IgG127,28,46,47. The produced IgG Fc-glycoforms 
(asialylated/unmodified; galactosylated; sialylated with (+) or without (−) fucose (F) or bisecting GlcNAc (B)) 
were characterized by tandem liquid chromatography and mass spectrometry (Fig. 1b and Supplemental Fig. S1), 
and show the expected glycan features. Levels of di-galactosylation and di-sialylation of those IgG glycoforms 
enriched in galactose and sialic acid, were highly elevated above that of mono-galactosylated and mono-sialylated 
IgG species (Fig. 1b and Supplemental Fig. S1). In addition, IgG1 with Fab glycosylation sites (known to have high 
level of α2,6-sialic acid)36,48 were produced and sialylation levels were verified by performing a Sambucus nigra 
agglutinin (SNA)-ELISA assay (Fig. 1c).
Human CD23 and DC-SIGN expressed on human embryonic kidney cells recognize natural lig-
ands. Human CD23 and DC-SIGN are normally expressed on cell surfaces as multimers (reported as trimers 
and tetramers, respectively) with intertwined C-type lectin domains held together by an α-helical coiled-coil stalk26. 
In order to mimic this native configuration, we generated human embryonic kidney (HEK) 293 Freestyle cells sta-
bly expressing either human CD23 or DC-SIGN. FcγRIIa (CD32a)-expressing HEK cells were generated and used 
as positive control for low affinity IgG binding. FACS results showed that human FcγRIIa, CD23 and DC-SIGN 
were specifically recognized by antibodies directed against the corresponding receptor (Fig. 2a–c and Supplemental 
Fig. S2 for representative histograms). To verify the functionality of each receptor, we tested the binding to their 
natural ligands (IgG1 for FcγRIIa; IgE for CD23; ICAM-3 for DC-SIGN) in FACS, and found that each receptor 
specifically recognized and bound their ligand. (Fig. 2a–c and Supplemental Fig. S2 for representative histograms).
Soluble human IgG1 glycoforms do not bind to CD23- or DC-SIGN-expressing cells. In order 
to investigate binding to human IgG1, we then tested binding of the IgG1 glycoforms to the cells by FACS, in the 
presence of calcium. No binding was observed at 37 °C for cells expressing either CD23 or DC-SIGN, not even 
3Scientific RepoRts |          (2019) 9:9995  | https://doi.org/10.1038/s41598-019-46484-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
for the Fab-sialylated or the most prevailing naturally-occurring sialylated Fc-glycoform (+F−B) (Fig. 2d and 
Supplemental Fig. S2 for representative histograms). Also, a lower binding temperature (4 °C) or lower IgG1 con-
centrations did not result in binding (Supplemental Fig. S2). In contrast, substantial binding was observed for all 
Fc- and Fab-glycosylated IgG1 to the low affinity FcγRIIa.
Figure 1. Generation of glyco-engineered human IgG1. (a) Schematic representation of glyco-engineered IgG1 
antibodies generated in this study with their biantennary glycan on asparagine (Asn) 297 (white star) in the Fc CH2 
domain and, for the Fab-glycoform, on Asn 29 and Asn 86 (orange stars) in the VH and VL domain, respectively. 
(b) Bar graph summarizing Fc-glycoform N-glycan profile of variable glycan end groups (fucose (+/−F), in 
red; bisecting GlcNAc (+/−B) in cyan; mono-/di-galactose in pale/dark yellow; mono-/di-sialic acid in pale/
dark purple) determined by mass spectrometry as percentages (%) of total glycosylation. N-glycan structures are 
schematically represented; galactose (yellow circle); mannose (green circle); N-acetylglucosamine (blue square); 
bisecting N-acetylglucosamine (cyan square); fucose (red triangle); sialic acid (purple diamond). (c) Bar graph 
showing the level of sialic acid of Fab-glycosylated anti-TNP as determined by Sambucus nigra agglutinin (SNA)-
lectin ELISA with high sialic acid Fab-glycoform (grey bar) to asialylated (unmodified) IgG1 without a Fab-glycan 
(white bar). Data are representative of three independent experiments (in triplicate) showing mean ± standard 
error of the mean (s.e.m.). Statistical analysis was performed by a Two-tailed paired t-test (**P < 0.01).
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CD23/DC-SIGN-expressing cells do not bind to immobilized IgG1 glycoforms. Although the low 
affinity binding of human CD23 to IgE (Fig. 2b and Supplemental Fig. S2) and ICAM-3 binding to DC-SIGN 
(Fig. 2c and Supplemental Fig. S2) was detected by FACS, we could not rule out that even lower affinity inter-
actions were not being detected in these assays. Therefore, and to study potential avidity-dependent interac-
tions between human IgG1 and CD23/DC-SIGN, cellular Surface Plasmon Resonance imaging (cSPRi) tests 
were performed. Here we used trinitrophenyl-conjugated human serum albumin (HSA-TNP) as a model anti-
gen which was spotted onto the sensor. Anti-TNP IgG1 glycoforms were injected and binding and formation 
of antigen-antibody complexes was observed in real-time (Fig. 3a; 1–2). This was followed by the injection of 
the generated cell lines (Fig. 3a; 3). First, without flow, the cells were allowed to sediment and interact with the 
antigen-bound antibodies in the presence of calcium (Fig. 3a; 4). Subsequently, the immune-complex-bound 
cells were washed with increasing flow speed (Fig. 3a; 5). Importantly, none of the cell lines showed binding to 
the negative control spots (Fig. 3b). Compared to Mock-transfected cells, FcγRIIa-expressing HEK cells bound 
asialylated IgG1 and, as expected, no binding was observed for Mock-, CD23-, or DC-SIGN-expressing HEK 
cells (Fig. 3b). Both CD23- and DC-SIGN-expressing cells showed an increased binding response on spotted 
anti-CD23 and anti-DC-SIGN, respectively (Fig. 3c). Similarly, the FcγRIIa-expressing HEK cells showed binding 
to anti-CD32 on the SPRi-sensor.
Importantly, no significant binding of CD23-, DC-SIGN-, or Mock-expressing HEK cells was observed to 
human IgG1 with varying degrees of Fc-glycan sialylation (Fig. 4a–c), irrespective of the presence or absence of 
fucose and/or bisecting GlcNAc moieties (Fig. 4c–f). Moreover, the presence of sialylated Fab-glycans did not 
trigger the binding of any of these cells (Fig. 4g). In addition, varying the HSA-TNP antigen density level either 10 
times higher or lower (100 and 1 nM) did not show specific binding of CD23/DC-SIGN-expressing cells to Fc- or 
Fab-sialylated IgG1 (Supplemental Fig. S3).
Discussion
In this study, we found no evidence that human IgG1 binds either native CD23 or DC-SIGN regardless of the 
sialylation status of IgG, whereas binding of these receptors to their native ligands was easily detected. These 
data are, however, in full agreement with those of Crispin et al. who also found no binding of sialylated IgG Fc to 
DC-SIGN30,40. Here, we investigated the binding in more detail by using a biosensor platform, which allowed us 
to study avidity interactions, and the study was extended by including CD23. In addition, the context of the IgG 
Figure 2. CD23 and DC-SIGN are functionally expressed on transfected HEK Freestyle cells, but do not bind 
human IgG1, regardless of sialylation status. (a–c) HEK Freestyle cells were transfected with human FcγRIIa 
(CD32, red), CD23 (blue), DC-SIGN (green), or an empty vector (Mock, pink) and tested for binding to 
anti-CD32, anti-CD23. or anti-DC-SIGN, or their natural ligands at 37 °C: asialylated IgG1, IgE, or ICAM-3, 
respectively. (d) Binding of different soluble IgG1 glycoforms (10 μg/ml) to HEK CD23, DC-SIGN, FcγRIIa 
and Mock transfected cells at 37 °C. Data are representative of three independent experiments (in duplicate) 
and shown as mean values of the geometric mean fluorescence intensity (gMFI ± s.e.m.) with the background 
signals subtracted. Significant differences compared to HEK Mock signals were determined by One-way 
ANOVA with Dunnett’s multiple comparisons test (*P < 0.05, **P < 0.01, ****P < 0.0001).
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sialylation was studied extensively, by including both Fab-sialylated IgG and altering the naturally-occurring var-
iable glycan adducts (fucose and bisecting GlcNAc) in the biantennary sialylated Fc-glycan, in any possible com-
bination. Still no binding could be detected, while binding was detected for the low affinity FcγRIIa which acted 
as a positive control. Taken together, these data do not support CD23 and DC-SIGN to be classified as true FcγRs.
Figure 3. Cellular SPR imaging layout and detection of receptor expression. (a) Schematic layout of the 
experimental setup for the cellular SPR, with HSA-TNP antigens depicted as red circles, SPR-sensor as 
yellow block, receptor-expressing cells as yellow circles with blue receptors and increasing gradient flow with 
a dashed arrow. (b) Representative sensorgram of five cellular SPRi runs on HSA-TNP- (10 nM) and HSA- 
(100 nM) (negative control) coated spots. Numbers depicted in the sensorgram correspond to the schematic 
representations in A, which shows the processes on the HSA-TNP spots at different time points. 1 IgG1 
glycoform (asialylated in this case) injection; 2 Anti-TNP glycoform binding to HSA-TNP spot; 3 Receptor-
bearing cell injection; 4 and 5 Cell sedimentation phase and start gradient flow respectively. 4a, 5a show cell 
binding and 4b, 5b no binding scenario. Green, blue and red backgrounds in the sensorgram represent the anti-
TNP glycoform immobilization, cell sedimentation and gradient flow (1–120 µl/s) phase, respectively. Each line 
represents the binding of a specific cell type (HEK FcγRIIa in red, HEK Mock in pink, HEK CD23 in blue, HEK 
DC-SIGN in green for the HSA-TNP spots) in resonance units (RU) to immobilized asialylated anti-TNP IgG1 
through time, with buffer flow (in yellow) to determine the background signal. (c) Representative sensorgrams 
show the binding of HEK FcγRIIa, HEK CD23 and HEK DC-SIGN cells to spots coated with murine antibodies 
against CD32, CD23 and DC-SIGN, respectively. These spots functioned as cell flow controls to confirm the 
presence of receptors. Significant differences compared to control (HEK Mock (panel B) or isotype control 
spots (panel C)) were based on the RU values on the last time point of the flow phase, determined by One-
way ANOVA with Tukey’s multiple comparisons test (**P < 0.01, ***P < 0.001, ****P < 0.0001). Data are 
representative of three independent experiments showing mean ± standard deviation (s.d.). Each line represents 
the average sensorgram, with s.d. as dotted lines, from at least three spots monitored in real time simultaneously.
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Part of the explanations for the opposing findings here and in literature concerning the binding of IgG to 
either CD23 and/or DC-SIGN14,17–19,21,23,25,30,31,33,40,42 may be due to differences in methodology and materials. For 
instance, most previous studies lack a characterization of the glycoforms used and relied on SNA-purified IgG 
from serum or IVIg, or ex vivo treatment of IgG or fragments thereof. Differences in used disease models may 
also be a reason for the apparent contradictions in literature. Many of these studies used human IgG in a murine 
context, which also introduces slight differences in structural composition of sialic acid between human and 
mice49–52. Other studies demonstrating binding of sialylated human IgG to DC-SIGN- or CD23-expressing CHO 
cells18,23, possibly introducing an incomplete human context e.g. the lack of α2,6-linked sialic acid, addition of 
alpha-Gal, and perhaps elevated level of mannose-containing structures52,53. In addition, in most in vivo studies 
human IgG was administered to mice which express SIGN-R1, potentially resulting in an incorrect translation 
from murine to human setting18,21,33,41.
Considerable part of the evidence for the binding between CD23/DC-SIGN to sialylated human IgG is based 
on predicted interactions between crystal structures. The structure of the sialylated human IgG1 Fc domain was 
determined by Ahmed et al. and showed that upon sialylation the Fc domain indeed undergoes a conformational 
change in the CE loop of the CH2 domain resulting in an increased interdomain flexibility29. However, no consid-
erable conformational differences can be observed in the IgG1 CH2-CH3 interphase where CD23 and DC-SIGN 
have been proposed to bind23. The group of Crispin et al. also determined the structure of the human sialylated 
Fc domain and was not able to observe conformational changes upon sialylation, even not in the CH2 domains30. 
Within the same group, Yu et al. demonstrated that there is no specific binding of IgG to DC-SIGN tetramers, 
regardless of sialylation status, and that serum IgG was not able to inhibit the binding of DC-SIGN to natural 
ligand HIV envelope glycoprotein gp12040. Therefore, these authors concluded that the direct binding between 
DC-SIGN and human IgG is uncertain. Another aspect of the proposed sialylation-induced “closed” IgG Fc state, 
is the major reduction (up to 10-fold) in binding affinity of IgG1 to conventional FcγRs18,22. Currently, evidence 
is growing that IgG Fc-sialylation does not or only subtly affect binding affinities to FcγRs54,55. While Subedi and 
Barb found a modest increase in affinity (1.16-fold) for afucosylated IgG1 to both FcγRIIa and FcγRIIIa/b55, our 
Figure 4. Neither human CD23- nor DC-SIGN-expressing cells bind human IgG1-containing immune 
complexes, regardless of glycosylation status. Cell flow sensorgrams after spot-specific buffer flow (background) 
subtraction (ΔRU). (a–g) Sensorgrams show binding responses to the different HSA-TNP (10 nM)-
immobilized IgG1 glycoforms (specific glycan depicted in inset) of HEK DC-SIGN and HEK CD23 compared 
to HEK Mock with HEK FcγRIIa as positive control. Line identities and sugar moieties are represented by 
different shapes as indicated in the figure legend. Data are representative of three independent experiments 
showing mean ± s.d. Each line represents the average sensorgram, with s.d. as dotted lines, from at least three 
spots monitored in real time simultaneously. Significant differences compared to HEK Mock were based on 
the RU values on the last time point of the flow phase, determined by One-way ANOVA with Tukey’s multiple 
comparisons test (***P < 0.001).
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group previously found a slight decrease (approximately 2-fold) in affinity of whole IgG1 for FcγRIIIa/b due to 
sialylation, but only when the Fc-glycan was also afucosylated and bisected7.
Our results do not imply that the function of IgG1 (or other subclasses) Fc-/Fab-sialylation or the involvement 
of C-type lectins (or other lectins, e.g. CD22) in IVIg therapy can be completely excluded. The mode of action 
of IVIg is complex, involving many underlying mechanisms that are both Fab- and Fc-mediated14,22. The most 
important mode of action is likely depending on its context. However, we conclude that a direct binding of either 
CD23 or DC-SIGN to sialylated IgG is very unlikely to occur. Therefore, these molecules should not be consid-
ered as bona fide receptors for IgG in humans.
Methods
Cloning. DNA encoding human DC-SIGN (AAK20997.1) was synthesized and codon-optimized by Geneart 
(Invitrogen, USA) and DNA encoding human CD23 cDNA (BC062591) and FcγRIIa 131 H (XM_017000664.1) 
was synthesized by Integrated DNA Technologies, USA. All constructs were generated with flanking HindIII 
and EcoRI restriction sites for cloning into pcDNA3.1 (+) expression vector (Invitrogen, USA) with ampicil-
lin and neomycin resistance genes using Rapid Ligation Kit (Thermo Scientific, USA). Ligation products were 
transformed into DH5α heat-shock competent cells (Thermo Scientific, USA). DNA sequences isolated from 
Ampicillin resistant clones were verified by Sanger sequencing in a 3730 DNA Analyzer.
Stable cell line production. HEK 293 FreeStyle cells were transfected with linearized empty, DC-SIGN, 
CD23 or FcγRIIa 131 H pcDNA3.1 expression vectors using 293fectin (Invitrogen, USA). These cell lines were 
cultured in suspension at 37 °C, 8% CO2 on a shaker in serum-free FreeStyle 293 Expression Medium (Gibco Life 
Technologies, USA) with 250 µg/ml Geneticin/G418 (PAA the cell culture company, Austria) added as selection 
marker. Receptor surface expression was monitored by flow cytometry.
Antibodies and other reagents. Human anti-TNP IgG1 production and glyco-engineering was per-
formed as described by Dekkers et al. for Fc-glycoforms8,43. In brief, vectors encoding p21, p27 and pSVLT and 
a single-gene construct encoding human anti-TNP IgG1 heavy chain and kappa light chain were transiently 
transfected into HEK 293 FreeStyle cells using 293fectin (Invitrogen, USA). To add bisecting GlcNAc to the 
N297 glycan, cells were co-transfected with a vector encoding GlcNAc transferase (GNTIII). To decrease fuco-
sylation, decoy substrate 2-fluorofucose (2FF) was added to the medium. For IgG1 galactosylation, D-galactose 
(Sigma-Aldrich Chemie N.V., The Netherlands) was added to the medium and cells were co-transfected with a 
vector encoding beta-1,4-galactosyltransferase (B4GALT1). For α2,6-sialylation, the latter treatment was com-
bined with co-transfection with a vector encoding beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GALT) and 
after purification these antibodies were further sialylated in vitro by incubation with recombinant ST6GALT 
enzyme and the substrate cytidine-5′-monophospho-N-acetylneuraminic acid. Unmodified anti-TNP IgG1 was 
used as a control for asialylation. For the Fab-glycoform, glycosylation sites in the VH and VL domain were 
introduced by substituting respectively the serine residue on position 29 and aspartic acid residue on position 
86 into asparagine. Constructs encoding the anti-TNP IgG1 heavy chain- (S29N) and kappa light chain- (D86N) 
Fab glycosylation were transfected into HEK cells in the same manner as the anti-TNP Fc-glycoforms. For all 
glycoforms, cell supernatant was harvested five days after transfection and purified using a HiTrap Protein A HP 
column (GE Healthcare, USA) on an ÄKTAprime plus system (GE Healthcare, USA). Commercially available 
antibodies and other reagents used in ELISA, FACS and cSPRi tests are depicted in Table 1.
Trypsin digestion and mass spectrometric glycosylation analysis. The IgG samples were dried in a 
centrifugal vacuum concentrator (Eppendorf, Germany) for 2 hours at 60 °C. Subsequently, the IgG was digested 
overnight at 37 °C in 40 µl (25 mM) ammonium bicarbonate (Sigma-Aldrich Chemie N.V., The Netherlands) con-
taining 200 ng trypsin (sequencing grade, Promega, Madison, WI). The resulting glycopeptides were analyzed by 
nanoLC-ESI-QTOF-MS on an RSLCnano Ultimate 3000 system (Thermo Fisher, The Netherlands) coupled to an 
Impact quadrupole-TOF-MS (micrOTOF-Q, Bruker Daltonics, Germany). The system and glycopeptide analysis 
are described in detail by Dekkers et al.43.
Lectin enzyme-linked immuno sorbent assay. To confirm the occupancy of the Fab glycosylation 
sites, lectin ELISA was performed as described previously by van de Bovenkamp et al.48. In brief, 96-well flat 
bottom plates (Nunc MaxiSorp, Denmark) were coated overnight with neuraminidase (New England Biolabs, 
USA)-treated mouse anti-human IgG diluted in PBS. Plates were incubated for 1 hour with 100 µl sample (25 ng/
ml) diluted in PBS supplemented with 0.02% Tween-20. Subsequently, plates were incubated with biotinylated 
Sambucus nigra agglutinin (SNA) for 2 hours for sialylation measurement. Then, plates were incubated with 
HRP-conjugated streptavidin for 10 minutes. In order to correct sialylation optical densities for total IgG, in 
parallel, total IgG levels were determined for all samples by incubating for 1 hour with HRP-conjugated mouse 
anti-human IgG. Plates were washed three times in between each incubation step and detection was performed 
with tetramethylbenzidine and stopped with 2 M H2SO4. Absorbance was measured at 450 and 540 nm on a 
BioTek plate reader.
Flow cytometry. HEK DC-SIGN/CD23/FcγRIIa/Mock-transfected HEK293 (1.5 ∙ 105 cells per well) 
were incubated, stained and washed in 20 mM HEPES (Sigma-Aldrich Chemie N.V., The Netherlands) buffer 
supplemented with 1 mM CaCl2 (Merck Chemicals B.V., The Netherlands), 1 mM MgCl2 (Merck Chemicals 
B.V., The Netherlands) and 1% BSA (Sigma-Aldrich Chemie N.V., The Netherlands), pH 7.4. After washing, 
directly-labeled samples were incubated with antibodies against the expressed receptor or natural ligand. 
Indirectly-labeled samples were incubated with either recombinant His-tagged human ICAM-3, human anti-TNP 
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IgG1 glycoforms or biotinylated mouse anti-CD32 and subsequently incubated with fluorescently labeled second-
ary antibodies/F(ab’)2 fragments or streptavidin. Incubation times were one hour and all steps were performed 
at 4 °C, except for the ligand and IgG glycoform 37 °C binding studies. Sample fluorescence was measured by a 
FacsCanto II cytometer (BD Biosciences, USA) and at least 10,000 events were recorded per sample. Reported 
data show geometric mean fluorescence intensities with the unstained cell signals (autofluorescence) subtracted.
Cellular surface plasmon resonance imaging. An Easy2Spot pre-activated SensEye P-type sensor 
(Ssens, The Netherlands) was spotted, in triplicate, with HSA-TNP7 (100, 10, 1 nM), HSA (100 nM) (Sanquin, 
The Netherlands) and antibodies against CD23/DC-SIGN/CD32 (100 nM) by a continuous flow microspotter 
(CFM) (Wasatch Microfluidics, USA). Spotting buffer consisted of 10 mM sodium acetate/acetic acid supple-
mented with 0.075% Tween-80 at pH 5.5, except for HSA and HSA-TNP, which was pH 4.0. Deactivation of the 
sensor was performed with 100 mM ethanolamine, pH 8.0 supplemented with 0.075% Tween-80 and 0.1% HSA 
in acetate buffer, pH 3.7 supplemented with 0.075% Tween-80. Analyte binding was performed in an IBIS MX96 
(IBIS Technologies B.V., The Netherlands). After injection, antibodies were allowed to bind to HSA-TNP spots for 
5 minutes. A short wash was performed to remove the unbound antibodies from the sensor. Subsequently, cells 
were injected and allowed to sediment/bind to immobilized glycoforms or control spots for 25 minutes56. During 
the next 11 minutes, the wash flow speed was increased stepwise from 1 to 120 µl/s. Regeneration was performed 
using glycine HCl pH 2.2 supplemented with 0.075% Tween-80.
In the first (antibody) flow either one of the human IgG1 glycoforms (100 nM) was injected into the flow 
chamber, in the second (cell) flow either HEK DC-SIGN/CD23/FcγRIIa/Mock (5.0 ∙ 106 cells per ml). System 
buffer consisted of 20 mM HEPES buffer supplemented with 1 mM CaCl2, 1 mM MgCl2 and 1% BSA, pH 7.4.
Data analysis. FACS data was analyzed using FlowJo software (FlowJo, USA). cSPRi data was analyzed using 
SprintX software (IBIS Technologies B.V., The Netherlands) and Rstudio software (RStudio, USA)57. Graphpad 
Prism 8.0.2 (GraphPad Software, Inc., USA) was used to generate sensorgrams and to perform statistical anal-
yses. To optimize visualization of the cell binding during sedimentation and flow phase in the cSPRi data, per 
HSA-TNP density, consecutively individual sensorgrams were normalized to the representative antibody binding 
plateau and buffer signals were spot-specifically subtracted for each time point.
Data Availability
We will make materials, data and associated protocols available to readers.
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